Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin In Moderate-To-Severe Atopic Dermatitis
Portfolio Pulse from Benzinga Newsdesk
Nektar Therapeutics has announced new statistically significant results from its Phase 1b study of Rezpegaldesleukin in moderate-to-severe atopic dermatitis. The company is also planning a new Phase 2a study for Rezpegaldesleukin in Alopecia Areata.
September 13, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nektar Therapeutics' Phase 1b study of Rezpegaldesleukin shows promising results, potentially boosting the company's stock in the short term.
The announcement of positive results from a clinical trial is typically seen as a positive development for a pharmaceutical company. This could lead to increased investor confidence in Nektar Therapeutics, potentially driving up the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100